OBESITY AND BREAST CANCER
ADIPOKINES’ ROLE
Keywords:
Breast cancer, obesity, adiponectin, leptinAbstract
Objective: Obesity and overweight are risk factors, and also prognostic factor for cancer, including breast cancer. Studies have accessed adipokines, adiponectins and leptins as keymediators in obesity and breast cancer. Methods: This is a systematic review of observational epidemiological cohort, case-control and survival studies related adiponectin and leptin with obesity and breast cancer over the past 15 years. Fourteen studies met the inclusion criteria, assessing the relationship of adiponectin and leptin as a risk factors and prognostic in breast cancer. Results: The studies showed an inverse relationship of adiponectin and direct relationship of leptin with body mass index (BMI) and were consistent in assigning lower serum levels of adiponectin to an increased risk of breast cancer, independently of BMI and variables of insulin resistance. Patients with breast cancer have low serum levels of adiponectin and higher levels of leptin in comparison to healthy patients. Low concentration of adiponectin increases the risk of breast cancer, and low concentrations of adiponectin and high of leptin are worse prognosis no matter the factors for breast cancer in women. Conclusion: The adipokines, in complex and interrelated mechanisms, probably drive breast cancer initiation and progression.
Downloads
References
Macis D, Guerrieri-Gonzaga A, Gandini S. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. Int J Epidemiol. 2014;43(4):1226-36.
Liu L-Y, Wang M, Ma Z-B, Yu L-X, Zhang Q, Gao D-Z, et al. The Role of Adiponectin in Breast Cancer: A Meta-Analysis. PLoS One. 2013;8(8):e73183.
Ye J, Jia J, Dong S, Zhang C, Yu S, Li L, et al. Circulating adiponectin levels and the risk of breast cancer: a metaanalysis. Eur J Cancer Prev. 2014;23(3):158-65.
Dieudonne MN, Bussiere M, Santos E, Leveneu MC, Giudicelli Y, Pecquery R. Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Bioph Res Commun. 2006;345:271-9.
Ishiawa M, Kitayama J, Nagawa H. Enhanced expression of leptina and leptina receptor (OB-R) in human breast cancer. Clin Cancer Res. 2004;10(13):4325-31.
Arita Y, Kihara S , Ouchi N, Takahashi M, Maeda K, Miyagawa J, et al. Paradoxical decrease of an adipose-specific protein,adiponectin in obesity. Biochem Biophys Res Commun. 1999;257(1):79-83.
Von Eynatten M, Schneider JG, Humpert PM, Rudofsky G, Schmidt N, Barosch P, et al. Decreased plasma lipoprotein lipase in hypoadiponectinemia: an association independent of systemic inflammation and insulin resistance. Diabetes Care. 2004;27(12):2925-9.
Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, et al. Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia. 2003;46:459-69.
Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 2011;12:1061-5.
Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CS. Longterm Metformin use in associated with decreased risk of breast cancer. Diab Care. 2010;33(6):1304-8.
Calip GS, Yu O, Elmore JG, Boudreau DM. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study. Cancer Cause Control. 2016;27(5):709-20.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Eni Devay de Freitas, Marco Antonio Vasconcelos Rego
This work is licensed under a Creative Commons Attribution 4.0 International License.
